Scholar Rock Holding Corp SRRK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SRRK is a good fit for your portfolio.
News
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock to Participate in Upcoming Investor Conferences
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer
-
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management
-
Scholar Rock Says FDA Clears Application for Trial of Obesity Treatment Apitegromab
Trading Information
- Previous Close Price
- $13.95
- Day Range
- $13.93–14.69
- 52-Week Range
- $5.56–21.08
- Bid/Ask
- $14.55 / $14.58
- Market Cap
- $1.13 Bil
- Volume/Avg
- 115,166 / 828,411
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (“TGFβ1”), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 150
- Website
- https://www.scholarrock.com
Comparables
Valuation
Metric
|
SRRK
|
VRDN
|
ARVN
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.71 | 2.91 | 3.26 |
Price/Sales | — | 1,810.15 | 22.34 |
Price/Cash Flow | — | — | — |
Price/Earnings
SRRK
VRDN
ARVN
Financial Strength
Metric
|
SRRK
|
VRDN
|
ARVN
|
---|---|---|---|
Quick Ratio | 8.58 | 17.93 | 4.93 |
Current Ratio | 8.80 | 18.26 | 4.98 |
Interest Coverage | −24.51 | −137.76 | — |
Quick Ratio
SRRK
VRDN
ARVN
Profitability
Metric
|
SRRK
|
VRDN
|
ARVN
|
---|---|---|---|
Return on Assets (Normalized) | −45.62% | −42.76% | −26.31% |
Return on Equity (Normalized) | −63.93% | −82.42% | −58.35% |
Return on Invested Capital (Normalized) | −46.79% | −50.70% | −63.59% |
Return on Assets
SRRK
VRDN
ARVN
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pqfdzrqrgc | Zwzjd | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Txwjtqcpf | Bgyrhm | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qhbzmwngk | Zxkwj | $97.8 Bil | |
MRNA
| Moderna Inc | Hlkbctlj | Jpkdx | $38.8 Bil | |
ARGX
| argenx SE ADR | Nhffpmrr | Ymqpc | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Phwhrkksd | Zmvnz | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nxbwzsfy | Tplppzg | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ytbqlrzh | Wtlrtcg | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hwfhmlbmz | Vmgmvld | $12.5 Bil | |
INCY
| Incyte Corp | Zmhcgymm | Yzqjdm | $11.5 Bil |